The FDA Has Accepted For Review Beigene's Supplemental New Drug Application For Brukinsa (Zanubrutinib) Combined With Obinutuzumab For Relapsed Or Refractory Follicular Lymphoma; Target Action Date Is In Q1 2024
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted BeiGene's supplemental new drug application for Brukinsa (Zanubrutinib) combined with Obinutuzumab for relapsed or refractory follicular lymphoma. The target action date is in Q1 2024.
July 12, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene's new drug application for Brukinsa combined with Obinutuzumab has been accepted by the FDA. This could potentially lead to increased revenues if the drug is approved.
The acceptance of BeiGene's new drug application by the FDA is a positive development for the company. If the drug is approved, it could lead to increased revenues for BeiGene. However, the target action date is in Q1 2024, so any potential impact on the company's revenues would not be immediate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100